PCOS has been officially renamed PMOS: Polyendocrine Metabolic Ovarian Syndrome. Dr. Evelin Dacker explains the HPA axis dysfunction driving the condition, the cardiovascular and inflammatory risks most physicians miss, and the treatment landscape beyond metformin and birth control.

GLP-1 medications are doing far more than simply suppressing appetite. These medications act on complex hormonal systems involving the brain, pancreas, stomach, fat tissue, insulin signaling, and energy expenditure. Understanding how semaglutide, tirzepatide, survodutide, and retatrutide actually work helps explain why they are changing the future of obesity and metabolic medicine.